Switch to
More onapp

How to use scorecard? Learn more

Remus Pharmaceuticals Ltd

REMUS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,154 cr, stock is ranked 1,295
High RiskStock is 6.24x as volatile as Nifty
7,948.300.00 (+0.00%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

High

Strong financials and growth story over the years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,154 cr, stock is ranked 1,295
High RiskStock is 6.24x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
PB RatioPB Ratio
60.34
Dividend YieldDiv. Yield
Sector PESector PE
43.83
Sector PBSector PB
5.97
Sector Div YldSctr Div Yld
0.59%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Remus Pharmaceuticals Limited is an India-based company that is engaged in the marketing and distribution of finished formulations of pharmaceutical drugs. It also deals in active pharmaceutical ingredients (API). The Company also provides technical consulting services to various distributors for the preparation of reports on the dossiers of the products. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, and tablet. The Company’s business verticals include the sale of finished formulations, the sale of APIs, and technical consulting. Its product portfolio comprises a range of therapeutic drugs, namely ACE inhibitors, analgesics, anti-erectile dysfunction, anti-fibrinolytics, anti-histamines, beta blockers, carcinoid tumors, chronic obstructive pulmonary disease, and contrast reagents, among others.

Financial TrendFinancial statements 

202120222023202419.2325.4446.61217.901.053.448.5121.53
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Cash Dividend 
Ex. DateMay 2, 2024

Interim 2 • Div/Share: ₹ 4

Cash Dividend 
Ex. DateOct 27, 2023

Interim • Div/Share: ₹ 2

Cash Dividend 
Ex. DateSep 15, 2023

Final • Div/Share: ₹ 2

See all events